MindMed doses first subject in trial of tablets for generalized anxiety disorder

US-based biotechnology company Mind Medicine (MindMed) has dosed the first subject in the 52-week Phase III Voyage study of MM120 orally disintegrating tablets (MM120 ODT) for the treatment of generalized anxiety disorder (GAD).